

Davidson, Mark

From: Davidson, Mark
Sent: Monday, July 10, 2017 11:46 AM
To: 'Rizwana Sproule'
Cc: 'Nadia Agopyan'; 'Alex Babayan'
Subject: RE: Kite Pharma 125643 Statistical /Clinical IR July 10, 2017

Dear Dr. Sproule,

We have reviewed your FDA July 6 IR Comment #3 competing risk analysis and have the following response:

Yes, the 2 non-relapse deaths need to be treated as competing risk in a competing risk analysis. Please provide the competing risk analysis results

by Wednesday, July 12, 2017.

Thank You

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."